Substituted benzamide derivatives and pharmaceutical compositions containing them

Abstract

Compounds of formula (I) and pharmaceutically acceptable salts thereof, where G is a methylene or ethylene linkage; R is hydrogen, C alkylO—; R is hydrogen, halogen, CN, N , trifluoromethyldiazirinyl, CF , CF O—, CF S—, CF CO—, C alkyl, C cycloalkyl, C cycloalkyl-C alkyl-, C alkylO—, C alkylCO—, C cycloalkylCO—, C cycloalkyl-C -alkylCO—, phenyl, phenoxy, benzyloxy, benzoyl and substituted benzoyl, phenyl-C alkyl-, C alkylSO —, (C alkyl) NSO — or (C alkyl)NHSO —; R is hydrogen, halogen, CN, N , trifluoromethyldiazirinyl, C alkylO—, C alkylS—, C alkyl, C cycloalkyl, C cycloalkyl-C alkyl-, C alkenyl, C alkynyl, CF CO—, C alkylCO—, C cycloalkylCO—, C cycloalkyl-C alkylCO—, phenyl, phenoxy, benzyloxy, benzoyl, phenyl-C alkyl-, or —NR R where R is hydrogen or C alkyl; and R is hydrogen, C alkyl, —CHO, —CO C alkyl or —COC alkyl; R is hydrogen, C alkyl, C alkenyl, or C alkynyl, are useful in the prevention and treatment of anxiety, mania, depression disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, etc.